SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals planning to file close to 20-25 ANDAs each year

19 Sep 2017 Evaluate

Glenmark Pharmaceuticals is planning to file close to 20-25 Abbreviated New Drug Applications (ANDAs) each year over the next five years and launch 10-20 products annually. The company’s pipeline of specialty products, to be rolled out over the next 3-4 years, is expected to act as a defence against generic price erosion and increase in competition, and boost profitable growth.

Glenmark’s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.



Glenmark Pharma Share Price

2290.00 -47.20 (-2.02%)
24-Apr-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.50
Dr. Reddys Lab 1312.40
Cipla 1295.00
Zydus Lifesciences 930.00
Lupin 2285.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×